enzalutamide,talazoparib
astellas,pfizer
['talapro,2', 'prostate', 'talazo', 'crpc', 'talapro-2']
breaking news #asco2023 dr. #karimfizazi presents the first results from all hrr positive 1st line mcrpc #prostatecancer patients (n=399)from our phase 3 talapro-2 trial talazoparib + enza significantly improves rpfs vs enza (hr 0.45), os trending well 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/ywWAdZmBWt